Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
AbCellera Biologics Inc (NASDAQ: ABCL) closed the day trading at $4.67 up 1.74% from the previous closing price of $4.59. In other words, the price has increased by $1.74 from its previous closing price. On the day, 3.68 million shares were traded. ABCL stock price reached its highest trading level at $4.81 during the session, while it also had its lowest trading level at $4.48.
Ratios:
For a better understanding of ABCL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.07 and its Current Ratio is at 11.07. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.14.
The Benchmark Company Upgraded its Hold to Buy on February 22, 2024, while the target price for the stock was maintained at $9.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1395550080 and an Enterprise Value of 984551680. For the stock, the TTM Price-to-Sale (P/S) ratio is 42.44 while its Price-to-Book (P/B) ratio in mrq is 1.38. Its current Enterprise Value per Revenue stands at 29.947 whereas that against EBITDA is -4.508.
Stock Price History:
The Beta on a monthly basis for ABCL is 0.65, which has changed by 0.7961539 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, ABCL has reached a high of $5.82, while it has fallen to a 52-week low of $1.89. The 50-Day Moving Average of the stock is 16.25%, while the 200-Day Moving Average is calculated to be 55.55%.
Shares Statistics:
Over the past 3-months, ABCL traded about 6.27M shares per day on average, while over the past 10 days, ABCL traded about 6215330 shares per day. A total of 298.65M shares are outstanding, with a floating share count of 225.43M. Insiders hold about 24.56% of the company’s shares, while institutions hold 35.33% stake in the company. Shares short for ABCL as of 1753920000 were 39805894 with a Short Ratio of 6.35, compared to 1751241600 on 30416351. Therefore, it implies a Short% of Shares Outstanding of 39805894 and a Short% of Float of 17.299999999999997.
Earnings Estimates
The market rating of AbCellera Biologics Inc (ABCL) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.14 and low estimates of -$0.18.
Analysts are recommending an EPS of between -$0.55 and -$0.65 for the fiscal current year, implying an average EPS of -$0.6. EPS for the following year is -$0.56, with 5.0 analysts recommending between -$0.21 and -$0.83.
Revenue Estimates
10 analysts predict $6.47M in revenue for the current quarter. It ranges from a high estimate of $9.72M to a low estimate of $4.67M. As of the current estimate, AbCellera Biologics Inc’s year-ago sales were $6.51MFor the next quarter, 10 analysts are estimating revenue of $7.02M. There is a high estimate of $11.24M for the next quarter, whereas the lowest estimate is $4.75M.
A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $42.28M, while the lowest revenue estimate was $30.68M, resulting in an average revenue estimate of $34.09M. In the same quarter a year ago, actual revenue was $28.83MBased on 9 analysts’ estimates, the company’s revenue will be $66.27M in the next fiscal year. The high estimate is $176.53M and the low estimate is $29.04M.
